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This study evaluates clinical, virological and immunological responses to antiretroviral (ARV) therapy based on
Lopinavir/ritonovir (LPV/r) in previously protease -inhibitor-experienced children. The study included 29 Brazilian
children (median age = 5.91 years) who had failed previous ARV therapy and had begun a regimen based on LPV/r.
At 12 months follow-up, a good virological response to LPV/r therapy was defined as achieving an undetectable viral
load or as a decrease in plasma HIV RNA levels to ≥ 1 log. A good immunological response was defined as an increase
in CD4+ cell count from baseline sufficient to attain a better CDC immune stage classification. The number of
infectious episodes 12 months before and 12 months after beginning LPV/r was assessed. Sixteen (55.2%) and 19
(65.5%) of 29 patients exhibited good virological and immunological responses, respectively. Baseline CD4+ values
(>500) predicted both virological and immunological responses (p<0.05). Older children were less likely to develop
an immunological response (p<0.001) than younger children. Nine children receiving 3 ARV drugs plus LPV/r
showed an immunological response (100%) compared to 10/20 (50%) children receiving 2 drugs plus LPV/r (p=0.01).
A lower number (n<5) of infectious episodes was noted after 12 months follow-up in children using the LPV/r
regimen (p=0.006). There was a positive correlation between children whose baseline CD4+ values were greater
than 500 cells/mm3 and virological responses. Although virological responses to therapy were seen in about half the
children (55.2%), the use of HAART containing LPV/r provided clinical and immmunological benefits.
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The use of highly active antiretroviral therapy (HAART)
has greatly improved the prognosis of HIV-1-infected children
[1-3]. However, in most pediatric studies the virological
responses to HAART are less well developed than those in
adults [4,5]. Poor adherence to therapy and low tolerability
are frequently cited as culprits, as are prior treatment
experience, the emergence of drug-resistent viruses, and
suboptimal pharmacokinetic properties of the drugs [6,7]. In
attempts to supplant some of these difficulties, therapeutic
regimens have been modified by the use of boosted protease
inhibitors (PIs) emploing ritonavir [8] or by the introdution of
co-formulations. The first boosted PI was developed as a fixed-
dose co-formulation of lopinavir/ritonavir (Kaletra). Lopinavir,
the active component of this combination, is extensively
metabolized by the P450 cytochrome (CYP) system, and
produces low systemic concentrations when used alone.
Ritonavir potently inhibits CYP3A4 and is used to enhance
systemic exposure to lopinavir [9].
Compared to other PIs, lopinavir/ritonavir may have
advantages in terms of pharmacokinetics, efficacy, and
resistance [7].
The aim of the present study was to evaluate factors
associated with clinical, virological and immunological




This longitudinal, single center, observational study was
conducted at the Pediatric AIDS Outpatient Clinic of the
Federal University of São Paulo, Brazil, from July 2001 to
July 2004.
Patients
Twenty-nine children met the inclusion criteria, which
consisted of having started highly active antiretroviral therapy
containing LPV/r after failing one or more previous regimens,
with a minimal follow-up period of 12 months.
Baseline characteristics of the study population are shown
in Table 1. Although all children were nucleoside analogue
and protease inhibitor experienced at abseline, ten children
(34.5%) had failed previous therapies consisting of 2
nucleoside analogues plus a single non-nucleoside analogue
(nevirapine or efavirenz). The reverse transcriptase inhibitor
regimens consisted of estavudine and didanosine (12/29;
41.4%), zidovudine and didanosine (7/29, 24.1%), estavudine
and lamivudine (4/29; 13.8%) or zidovudine and lamivudine
(3/29,10.3%). Four children (13.8%) were using double therapy
(estadudine plus didanosine or estavudine plus lamivudine)
at the time they started HAART with LPV/r.
The protease inhibitors most frequently used in the failed
schemes were ritonavir (6/29; 20.7%), nelfinavir (5/29; 17.2%)
and amprenavir (4/29; 13.8%).
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Laboratory Methods
Children underwent regular assessment of laboratory
parameters at intervals ranging from 4 to 5 months during
follow-up.
Plasma HIV-1 RNA was measured using a quantitative,
reverse transcriptase-polymerase chain reaction with a lower
detection limit of of 400 copies/mL (Roche Molecular Systems,
Branhburg, New Jersey, USA). Peripheral blood mononuclear
cells were assessed by flow cytometry (FACSCalibur, BD
Biosciences, USA) immediately after cell staining, and were
analyzed using CellQuest software (BD Biosciences, USA).
Statistical Analysis
All results are presented as medians and ranges.
Virological responses were classified into three categories:
group I included children with undetectable HIV-1 RNA values
(< 400 copies/mL) at 12 months follow-up (complete virological
responders); group II included children in whom plasma HIV-
1 RNA did not decline to undetectable levels, but showed a
sustained viral load drop ≥ 1 log at 12 months (partial
virological responders); group III comprised children with
treatment failures whose plasma HIV-1 RNA levels showed a
non-sustained drop or a drop of less than 1 log at 12 months
follow up (virological failures).
To evaluate immunological responses, children were
reclassified at the last time of follow up (12 months) according
to the CDC Classification System (1994)[10]. A good
immunological response was considered present when the
child’s immune stage changed from 3 to 2 or 1, or from 2 to 1.
Children who began the study classified as immune stage 1
and remained at this same level of classification at 12 months
follow up, were also considered as having a good
immunological response. Those who showed no
immunological improvement based on the above criteria were
considered to be immunological non-responders. Differences
between these categories of predictor variable were evaluated
using a univariate analysis of variance on ranked data. The
Chi-squared test (χ2) or Fisher exact test was used to compare
groups.  The threshold significance was set at p=0.05.
Statistical analyses were performed using the Stata Software
package version 7.0.
Clinical improvement was assessed by comparing the
number of infectious episodes 12 months before and 12
months after the introduction of HAART with LPV/r (HAART-
LPV/r).
Results
As shown in Table 1, the median baseline viral load values
were similar among the three groups studied. The median CD4+
counts (mCD4+) were higher in group I (complete virologial
responders; mCD4+=1,533, range 121–2,680) than for groups
2 and 3 (partial virological responders; mCD4+= 239, range 9–
692; and virological failures; mCD4+=201, range 7–1,198),
although the differences were not statistically significant.
At the last time of follow up, 11 patients showed full
complete virological responses (37.9%), 5 exhibited  partial
Table 1. Baseline characteristics of children in the study population
Complete virological Partial virological Virological Total
responders responders failure
N 11 5 13 29
Median age (years) 5.4 6.59 8.47 5.91
Clinical stage according to CDC* criteria
Non-C 5 4 6 15
C 6 1 7 14
Immunological stage according to CDC* criteria
Non-3 10 1 6 17
3 1 4 7 12
Median (IQ range) 4.7 (3.2-5.6) 5.07 (3.0-5.8) 4.9 (2.7-5.7) 4.84 (3.0-5.7)
  viral load (log10)
Median (IQ range) 1,533 (121-2,680) 239 (9-692) 201 (7-1,198) 486 (7-2,690)
  CD4 cell/mm3
Therapeutic history
Previous treatment 6 2 5 13
  without PI
Previous treatment 5 3 8 16
  with PI
Less than 3 prior 2 0 2 4
  ARV schemes
≥ 3 prior ARV schemes 9 5 11 25
* CDC, Centers for Disease Control and Prevention; IQ, interquatile range; PI, protease inhibitor.
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virological responses (17.2%) and 13 were virological
failures (44.8%). Considering the complete responders and
the partial responders as a single group, 16 (55.2%) children
were considered to be virological responders. Nineteen
children (65.5%) showed an increase in CD4+ cell counts
with improvement in CDC immune stage. Ten patients
(34.5%) showed no immunological improvement after 12
months of HAART with LPV/r. The failed therapeutic
schemes used prior to starting the study consisted of 2
NRTIs plus 1 PI (n=10), 2 NRTIs plus 1 NNRT (n= 10), 2
NRTI (n= 4), 1 NRTI plus 2 PIs (n=3), 3 NRTI plus 1PI (n=1),
1 NRTI plus 1 NNRTI plus 1 PI (n= 1). When considering
the number of ARV drugs that comprised the LPV/r scheme,
most children (n=20; 69%) received 2 ARV drugs plus LPV/
r, while 9 (31%) received 3 drugs plus LPV/r.
Twenty-three (86.21%) patients were very ARV-
experienced, having participated in 3 or more ARV schemes
prior to the present study.
The frequency and kind of infectious disease episodes
that occurred during the 12 months pre- and post-
introduction to HAART with LPV/r are given in Table 2.
The most frequent episodes concern respiratory system
diseases.
There were no significant differences between the
virological responders and non-responders in terms of age,
number of previous schemes, number of ARV drugs
associated with LPV/r, or PI use in the previous failed ARV
therapy. The only factors that influenced immunological
response were baseline age, baseline CD4+ values, and
number of ARV drugs associated with LPV/r. The univariate
analyses showed that older children (median age=11.48
years) were less likely to develop an immunological
response (p<0.001) than younger children (median age=5.2
years). Nine children receiving 3 ARV drugs plus LPV/r
presented an immunological response (100%) in contrast
to 10 of 20 (50%) children receiving 2 drugs (p=0.01).  A
lower number (n<5) of infectious episodes was observed
in children after 12 months follow up using the LPV/r scheme
[p=0.006; OR=0.16 (95% CI 0.03–0.76)].
Discussion
One of the most important characteristics of HIV-infected
children treated using HAART is the lower virological
response rates compared to adults. Further, achieving an
undetectable viral load is a difficult goal in HIV-1-infected
children undergoing antiretroviral therapy [11].  Our data show
that HAART with LPV/r induces beneficial effects in terms of
clinical, virological and immunological outcomes, even in
children highly previously exposed to ARV therapy.
Unexpectedly, the virological responses were not influenced
by factors like number of previous schemes, number of ARV
drugs associated with LPV/r or PI use in the previous failed
ARV therapies. Excluding difficulties with adherence to the
therapy, which were not assessed in this evaluation, we
expected children who had taken more drugs, and those who
had received PIs prior to LPV/r treatment, to have poor
virological responses; however, our data do not confirm this
supposition. Differently from our results, Resino et al found
that children with virological failure or VL rebound had a higher
baseline VL and lower CD4+ T-lymphocyte count/mm3, and
had taken a greater number of drugs prior to LPV/r [11].
Another study showed that baseline plasma HIV-1 RNA levels
affect the likelihood of achieving sustained viral suppression.
Also, durable virological and immunological benefits were
more likely to be achieved in children whose CD4+ lymphocyte
counts increased > 70 cells/mL by 20 weeks of therapy [12].
Although LPV/r has been considered suitable for  ‘salvage’
therapy because of its high barrier to the development of
resistance, most children studied (86%) were highly ARV-
experienced, and had probably accumulated several PI-
associated, resistance mutations, which may explain the high
percentage of children (44.8%) with virological failure.
Importantly, we have observed that, in agreement with
previous studies using HAART with different PIs [5,13-15],
CD4+ T cells increased significantly in most children (65%),
irrespective of the extent of virological suppression. Also,
three factors influenced the immunological responses: the
baseline age of the children, baseline CD4+ values, and number
of ARV drugs associated with LPV/r. The fact that older
children (median age=11.48 years) were less likely to develop
an immunological response than younger children (median
age=5.2 years) probably reflects significant impairment of the
immune system in the latest stages of HIV infection. Further,
thymus function is critical for the regeneration and
reconstitution of T-cell populations in hosts subjected to
prolong, extreme T-cell depletion. We observed a significant
increase in the percentage of children exhibiting an
immunogical response when a more potent therapy was used.
Nine children receiving three ARV drugs plus LPV/r showed
immunological response (100%), in contrast to 10 of 20 (50%)
children receiving two drugs plus LPV/r (p=0.01). A recent
study has correlated immune system recovery in heavily
pretreated, HIV-infected children, in response to salvage
therapy with LPV/r, to a decrease in immune system activation
and an increase in thymus function [16]. Further, restoration
Table 2. Type and frequency of infectious disease events in
the study population
Antiretroviral Therapy in Children
Infectious disease event Episodes (n) %
URI/ common cold 84 30.9
Tonsilitis 12 4.4
Otitis media, acute 25 9.2
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of thymus function and a higher thymus output may play a
critical role in sustaining peripheral CD4+ cell increases despite
the persistence of viral replication. In the present study,
although the use of a more aggressive therapy (three versus
two drugs plus LPV/r) is associated with a better
immunological response, aspects such as toxicity, adverse
events and the quality of life should be considered [5,17].
The clinical impact of HAART with LPV/r in the population
studied could also be seen in terms of the reduction in the
number of infectious events.  After 12 months observation,
the children showed a lower number (n<5) of infectious
episodes  [p=0.006; OR=0.16 (95% CI 0.03–0.76)]. Shifts in co-
receptor usage (from SI/X4 to NSI/R5) after LPV/r salvage
therapy have been related to clinical efficacy [18].
The most frequent infections observed in this group were
URI/ common cold (31%), otitis (17.3%) and pneumonia (11%).
Although some of these afflictions are considered “common
childhood infections”, they can have a serious impact on
immunodeficient children infected with HIV. The small number
of opportunistic infections found during the study period
(one case of CMV, one case of cryptococcosis and 3 cases of
herpes zoster) did not allow separate analysis.
In summary, the efficacy of highly active antiretroviral
therapy is strictly dependent on its ability to control HIV-1
replication. Issues regarding potency of the employed drugs,
adherence to therapy and development of drug resistance are
the major determinants of treatment failures. In this study,
HAART including LPV/r provided beneficial effects in terms
of clinical, immunological and virological outcomes even in
highly ARV experienced children.
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